We are living in unprecedented times, as cases of coronavirus (COVID-19) rapidly increase while the world struggles to contain the pandemic. The biotechnology industry has stepped up to help combat this public health threat, working tirelessly to develop potential treatments, diagnostics and…

Writing for Morning Consult, BIO’s Jim Greenwood discusses the challenges of developing novel antibiotics and highlights the urgent need for policies that incentivize innovators to produce new ones. “The reason why so few antibiotics are being developed is simple – the market is broken. Estimates…

On behalf of the team at BIO, we send our deepest condolences to the family of Dr. John Holaday who tragically passed away. Dr. Holaday’s career was nothing short of inspiring. After earning his Ph.D. from the University of California, San Francisco School of Medicine, he served at the Walter Reed…

On Tuesday, October 8, BIO formally announced that its President and CEO Jim Greenwood would be stepping down from the world's largest biotechnology organization in January 2021. In a letter to BIO staff, Greenwood reflected on his rise to BIO and the accomplishments the organization has achieved…

BIO’s Jim Greenwood joined CSPAN’s Washington Journal for a conversation about drug pricing, the latest proposals being considered on Capitol Hill, the need to sustain biomedical innovation, and ways to ensure patients have access to the medicines they need with out-of-pocket costs they can afford…

In a piece for Morning Consult, BIO’s Jim Greenwood writes that while CAR-T cell therapies are changing the way we treat patients with some types of cancer, policies being considered in Washington could delay access to care for individuals covered under Medicare. “While CAR-T therapies represent a…

Summary: BIO CEO Jim Greenwood gave the following keynote address at the BIO 2019 International Convention today in Philadelphia, highlighting how politicians and patients are talking about different things when discussing drug costs in the United States and why represents a threat to…

Just moments after it was announced the FDA had approved a new treatment for spinal muscular atrophy, Dr. Peter Bach was warning about a “break down” in the U.S. drug pricing system. It’s unfortunate Dr. Bach would respond to the discovery of a miracle cure for a fatal disease with such doom and…

BIO represents pioneers in the world’s most innovative industry. It’s our job to support and advocate for our members as they pursue cutting-edge scientific and technological advancements — from finding new ways to treat cancer to enhancing the very food we eat to creating a sustainable environment…

Writing for The Atlantic, Dr. Ezekiel Emanuel accuses the biopharmaceutical industry of being “deceptive” when it seeks to explain the cost of prescription drugs. But in making this claim, Dr. Emanuel is guilty of engaging in some of his own acts of deception. For starters, drug prices are not …